Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
04 8월 2023 - 5:05AM
Virios Therapeutics, Inc. (Nasdaq:
VIRI) (the
“Company”), a development-stage biotechnology company focused on
advancing novel, combination antiviral therapies to treat
debilitating chronic diseases, including fibromyalgia (“FM”) and
Long-COVID, announced today that it will report second quarter 2023
financial results on Thursday, August 10, 2023 before the open of
the financial markets. Management will also host a webcast and
conference call on August 10, 2023 at 8:30 a.m. ET to discuss the
results and provide a corporate update.
The live and archived webcast of the call may be
accessed on the Virios Therapeutics website under the Investors
section: Events and Presentations. The live call can also be
accessed by dialing 888-506-0062 (domestic) or 973-528-0011
(international) and asking to be connected to the “Virios
Therapeutics Conference Call” using the access code: 133321.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a
development-stage biotechnology company focused on advancing novel
antiviral therapies to treat diseases associated with a viral
triggered abnormal immune response such as fibromyalgia (“FM”) and
Long-COVID. Overactive immune response related to activation of
tissue resident herpesvirus has been postulated to be a potential
root cause of chronic illnesses such as FM, irritable bowel
syndrome, Long-COVID, chronic fatigue syndrome and functional
somatic syndrome, all of which are characterized by a waxing and
waning manifestation of disease, often triggered by events which
compromise the immune system. Our lead development candidates are
novel, proprietary, fixed dose combinations of an antiviral
compound and celecoxib designed to synergistically suppress
herpesvirus replication, with the end goal of reducing virally
promoted disease symptoms. IMC-1 (fixed dose combination of
famciclovir and celecoxib) has been granted fast track designation
by the FDA. The Company plans to engage the FDA in the latter half
of 2023 with the goal of filing an investigational new drug
application to formally assess IMC-2 (fixed combination of
valacyclovir and celecoxib) as a potential treatment for Long-COVID
sequelae.
For more information, please visit
www.virios.com.
Follow Virios Therapeutics
Email Alerts:
https://ir.virios.com/resources/email-alerts
LinkedIn:
https://www.linkedin.com/company/viriosbiotech/
Twitter: https://twitter.com/ViriosBiotech
Facebook:
https://www.facebook.com/ViriosBiotech/
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements,” within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995, that are subject
to substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Forward-looking statements contained in
this press release may be identified by the use of words such as
“anticipate,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,”
“would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Virios
Therapeutics’ current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict,
including risks related to the completion, timing and results of
current and future clinical studies relating to Virios
Therapeutics’ product candidates. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. These and other risks and uncertainties
are described more fully in the section titled “Risk Factors” in
the Annual Report on Form 10-K for the year ended December 31,
2022, filed with the Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date, and Virios Therapeutics, Inc. undertakes no duty
to update such information except as required under applicable
law.
Contact:IR@Virios.com
Source: Virios Therapeutics, Inc. (VIRI)
Virios Therapeutics (NASDAQ:VIRI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Virios Therapeutics (NASDAQ:VIRI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024